Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 ( MK2 ) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > MAPKAPK2 (MK2)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.